Study of JYP0322 for ROS1 fusion-positive solid tumors
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called JYP0322 for people with advanced solid tumors that have a specific genetic change called a ROS1 fusion. The goal is to see if the drug is safe and effective against these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor that has spread or cannot be removed, and it must have a ROS1 fusion.
- Your tumor must be measurable on scans (like CT or MRI).
- You must be expected to live at least 3 more months.
- You cannot have certain stomach or gut problems that could affect how the drug is absorbed.
- You cannot have a history of severe allergies to any ingredient in the study drug or be currently in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
This trial tests a new drug called JYP0322 against standard chemotherapy for people with advanced lung cancer that has a specific genetic change called ROS1. It's for those who have already tried one or two ROS1-targeted treatments and need another option.
This trial tests a new drug called JYP0035 alone in people with advanced solid tumors. It aims to see if the drug is safe and effective.
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This trial tests a new drug called YL-17231 in people with advanced solid tumors that have specific changes (mutations) in the KRAS, HRAS, or NRAS genes. It is for patients whose cancer has stopped responding to or cannot tolerate standard treatments.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.